TREXIMET (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the TREXIMET drug offered from GlaxoSmithKline LLC. This Serotonin 1b Receptor Agonists [MoA],Serotonin 1d Receptor Agonists [MoA],Serotonin-1b and Serotonin-1d Receptor Agonist [EPC],Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
| NON-PROPRIETARY NAME: | sumatriptan and naproxen sodium |
| SUBSTANCE NAME: | SUMATRIPTAN SUCCINATE; NAPROXEN SODIUM |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Serotonin 1b Receptor Agonists [MoA],Serotonin 1d Receptor Agonists [MoA],Serotonin-1b and Serotonin-1d Receptor Agonist [EPC],Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2008-04-25 |
| END MARKETING DATE: | 2018-07-31 |
TREXIMET HUMAN PRESCRIPTION DRUG Details:
| Item Description | TREXIMET from GlaxoSmithKline LLC |
| LABELER NAME: | GlaxoSmithKline LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 85; 500(mg/1; mg/1) |
| START MARKETING DATE: | 2008-04-25 |
| END MARKETING DATE: | 2018-07-31 |
| PRODUCT ID: | 0173-0750_33607e05-3cfe-4e44-9a3b-aec5d2062c8e |
| PRODUCT NDC: | 0173-0750 |
| APPLICATION NUMBER: | NDA021926 |
Other SUMATRIPTAN SUCCINATE; NAPROXEN SODIUM Pharmaceutical Manufacturers / Labelers:
